716 related articles for article (PubMed ID: 16645583)
21. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
22. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
23. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
24. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
25. Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both CD8(+) T cell and CD4(+) T cell epitopes.
Takemoto S; Nishikawa M; Guan X; Ohno Y; Yata T; Takakura Y
Mol Pharm; 2010 Oct; 7(5):1715-23. PubMed ID: 20695521
[TBL] [Abstract][Full Text] [Related]
26. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
28. Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope fused to mouse heat shock protein 70 via polyhistidine conjugation.
Takemoto S; Nishikawa M; Otsuki T; Yamaoka A; Maeda K; Ota A; Takakura Y
J Control Release; 2009 Apr; 135(1):11-8. PubMed ID: 19100299
[TBL] [Abstract][Full Text] [Related]
29. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
30. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
31. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.
Eriksson K; Sun JB; Nordström I; Fredriksson M; Lindblad M; Li BL; Holmgren J
Eur J Immunol; 2004 May; 34(5):1272-81. PubMed ID: 15114660
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
33. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
Rosalia RA; Quakkelaar ED; Redeker A; Khan S; Camps M; Drijfhout JW; Silva AL; Jiskoot W; van Hall T; van Veelen PA; Janssen G; Franken K; Cruz LJ; Tromp A; Oostendorp J; van der Burg SH; Ossendorp F; Melief CJ
Eur J Immunol; 2013 Oct; 43(10):2554-65. PubMed ID: 23836147
[TBL] [Abstract][Full Text] [Related]
35. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
38. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
39. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.
Viehl CT; Tanaka Y; Chen T; Frey DM; Tran A; Fleming TP; Eberlein TJ; Goedegebuure PS
Breast Cancer Res Treat; 2005 Jun; 91(3):271-8. PubMed ID: 15952060
[TBL] [Abstract][Full Text] [Related]
40. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
